At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 37 enrolled
Drug / intervention
Dapsonedrug
Likely dose
Dapsone 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers
Texas Tech University Health Sciences Center·interventional·Posted Jul 20, 2010·Updated Jul 21, 2016
In Brief
A Phase 4 clinical trial evaluating Dapsone for Obesity and 2 related conditions. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Leprosy, Tuberculosis
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR)
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedJul 2010
Primary CompletionMay 2012
TodayJul 2026
First PostedJul 20, 2010
Enrollment StartJul 1, 2010
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.0 years ago
Interventions
Dapsonedrug
100 mg PO x 1 dose